Conditional Reprogramming for Patient-Derived Cancer Models and Next-Generation Living Biobanks

作者：Nancy Palechor-Ceron, Ewa Krawczyk, Aleksandra Dakic, Vera Simić, Hang Yuan, Jan Blancato, Weisheng Wang, Fleesie Hubbard, Yun‐Ling Zheng, Hancai Dan, Scott E. Strome, Kevin J. Cullen, Bruce J. Davidson, John F. Deeken, Sujata Maiti Choudhury, Peter H. Ahn, Seema Agarwal, Xuexun Zhou, Richard Schlegel, Priscilla A. Furth, Chong-xian Pan, Xuefeng Liu · 发表于：Cells · 年份：2019 · DOI：10.3390/cells8111327 · 被引用次数：84 · 研究领域：Cancer Genomics and Diagnostics、Cancer Cells and Metastasis、Cancer Research and Treatments

Traditional cancer models including cell lines and animal models have limited applications in both basic and clinical cancer research. Genomics-based precision oncology only help 2–20% patients with solid cancer. Functional diagnostics and patient-derived cancer models are needed for precision cancer biology. In this review, we will summarize applications of conditional cell reprogramming (CR) in cancer research and next generation living biobanks (NGLB). Together with organoids, CR has been cited in two NCI (National Cancer Institute, USA) programs (PDMR: patient-derived cancer model repository; HCMI: human cancer model initiatives. HCMI will be distributed through ATCC). Briefly, the CR method is a simple co-culture technology with a Rho kinase inhibitor, Y-27632, in combination with fibroblast feeder cells, which allows us to rapidly expand both normal and malignant epithelial cells from diverse anatomic sites and mammalian species and does not require transfection with exogenous viral or cellular genes. Establishment of CR cells from both normal and tumor tissue is highly efficient. The robust nature of the technique is exemplified by the ability to produce 2 × 106 cells in five days from a core biopsy of tumor tissue. Normal CR cell cultures retain a normal karyotype and differentiation potential and CR cells derived from tumors retain their tumorigenic phenotype. CR also allows us to enrich cancer cells from urine (for bladder cancer), blood (for prostate cancer), and p...